{"name":"Theratechnologies","slug":"theratechnologies","ticker":"TH","exchange":"TSX","domain":"theratech.com","description":"Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. It operates through Hospitality & Facilities Services – South, Workforce Hospitality Solutions, and Government segments. The company owns a network of specialty rental accommodation units. It also provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. In addition, the company offers construction services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas.","hq":"Montreal, Quebec, Canada","founded":1993,"employees":"902","ceo":"Paul Bhatt","sector":"HIV / Oncology","stockPrice":13.82,"stockChange":0.09,"stockChangePercent":0.66,"marketCap":"$1.4B","metrics":{"revenue":320635000,"revenueGrowth":7.3,"grossMargin":31.1,"rdSpend":0,"netIncome":-37121000,"cash":8348000,"dividendYield":0,"peRatio":44.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2010-01-01","label":"Egrifta first approved","drug":"Egrifta","drugSlug":"tesamorelin-acetate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Tesamorelin patent cliff ($0.0B at risk)","drug":"Tesamorelin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Placebo-Control","genericName":"Placebo-Control","slug":"placebo-control","indication":"Other","status":"marketed"},{"name":"Placebo for Tesamorelin","genericName":"Placebo for Tesamorelin","slug":"placebo-for-tesamorelin","indication":"Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"TH9507","genericName":"TH9507","slug":"th9507","indication":"HIV-associated lipodystrophy","status":"phase_3"},{"name":"HIV Anti-retroviral Background Therapy","genericName":"HIV Anti-retroviral Background Therapy","slug":"hiv-anti-retroviral-background-therapy","indication":"HIV-1 infection","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Egrifta","genericName":"TESAMORELIN ACETATE","slug":"tesamorelin-acetate","indication":"Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy","status":"marketed"}]}],"pipeline":[{"name":"Placebo-Control","genericName":"Placebo-Control","slug":"placebo-control","phase":"marketed","mechanism":"Placebo-Control is not an active pharmaceutical agent but rather an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.","indications":[],"catalyst":""},{"name":"Egrifta","genericName":"TESAMORELIN ACETATE","slug":"tesamorelin-acetate","phase":"marketed","mechanism":"Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone.","indications":["Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy"],"catalyst":""},{"name":"TH9507","genericName":"TH9507","slug":"th9507","phase":"phase_3","mechanism":"TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions.","indications":["HIV-associated lipodystrophy"],"catalyst":""},{"name":"HIV Anti-retroviral Background Therapy","genericName":"HIV Anti-retroviral Background Therapy","slug":"hiv-anti-retroviral-background-therapy","phase":"phase_2","mechanism":"Inhibits HIV replication by targeting the CCR5 receptor","indications":["HIV-1 infection"],"catalyst":""},{"name":"Placebo for Tesamorelin","genericName":"Placebo for Tesamorelin","slug":"placebo-for-tesamorelin","phase":"phase_3","mechanism":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Theratechnologies Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Theratechnologies reported its financial results for the fourth quarter and full year 2023, highlighting a net loss of $13.4 million and $54.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Theratechnologies Announces Collaboration with University of Montreal","summary":"Theratechnologies announced a collaboration with the University of Montreal to develop new treatments for HIV and oncology.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVldMaFR0TFYzNzN6RWNReU9lV3hxcGtkMTZaR1BOVVpiZWlwSWlXaVlDOVJ3T1ViWkRKQmh5VDU0NEVqdnd3NmpTdDhyelV6TGVreFJLS1VEUHZCaUt2TGY3MDdnVHBCaHh0MUZGekdBMW15UWpEZS01U1RHRXVPSTVGdGZ3UnpwR1ZlYVpwVE1yajVNaW5DMkFKN3dhY194c3VmdVh3?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Theratechnologies Announces Completion of Acquisition by Future Pak - Yahoo Finance","headline":"Theratechnologies Announces Completion of Acquisition by Future Pak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1ON0htdGZBVE53QXlCZjc5RGRETkpZQlk2X0o2VmEwU2Iwc1R2VWdSdi1lcVpTNHJMdmhPQUlBakZheFdrSzByXzJuR2lVMWVjVk9FYg?oc=5","date":"2025-07-08","type":"pipeline","source":"The Pharma Letter","summary":"Future Pak - The Pharma Letter","headline":"Future Pak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFA4QkxYUWktN29lNm93QWFjVWxsX2dCV0pUT0tQcEJQQnFtaVp1RFRsR1JLWF9RVXU0bmVUVDRsQ0tscUU4d2R0bHJDVXNSclM3MWZ3?oc=5","date":"2025-07-03","type":"deal","source":"firstwordpharma.com","summary":"Theratechnologies set for $254M buyout by contract manufacturer Future Pak - firstwordpharma.com","headline":"Theratechnologies set for $254M buyout by contract manufacturer Future Pak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNMHphNUNJX2NPMUNvYjVKcDAyWU9IcDVKT3BFVzM2cVB0VXA3MGZNcVAxYjU2YTNzdWJidUVXOEVhNHpJbmhYd3NRS3hObnAwUHhFelRWTncySWpncnhLTDRDVXN2SjhWc3RscVRpRmlxWGdlM2JMWVpOSkdJTTUwRUNOWVh2VVJ1V281ZDFPWHFOMFA4ejZaV2lkSUgwMnNMMDI4MWd4Uy1DRXIwRjc4UA?oc=5","date":"2025-07-03","type":"pipeline","source":"Pharmaceutical Technology","summary":"Theratechnologies shares surge 25% amid $254m Future Pak takeover - Pharmaceutical Technology","headline":"Theratechnologies shares surge 25% amid $254m Future Pak takeover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNT1NZb1laNnJJTmd2SW9UZTBsaFdwb1dLR250WGlzc2FDVHdTV2lEMVlKcmt4bkM2Q2syZXA0Q3FuZVFBb0xKZVRadi1jSzdzQnNaVGF1WVA0cHY3ZmdIbFVyNGpZUjRNRHEyblJ4SnpId1gxNjV3X3NFNzhuVzgyZmhESG9FUW9xU0dqbHE2QUt6V2ZURmdYY3V5enNIT0ZnekFsSVVDeV9uYVI0RHlnTkVRSlBOM1lTWEFuMA?oc=5","date":"2025-04-14","type":"deal","source":"BioSpace","summary":"Theratechnologies in Talks with Anonymous Potential Buyer While Fielding Future Pak Buyout Offer - BioSpace","headline":"Theratechnologies in Talks with Anonymous Potential Buyer While Fielding Future Pak Buyout Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbjVab2tIYVV0NVJiNWFHZU5tRGtmdU85aFNGdXNTM1o2Z1RscmhQaXNNT2tPY1A0SkNSQ0JrMFh0XzAwVG9PU1ZSdWJ5UU9qNHNtSUNRNzBFZmJvc1N2YnZaemh3TkQ5TkVrNnZTMGp1RmRkcU8yZlVKYUt4RW1jTkZRTUJqMEFlVmRXYks2YUIyeHdNeEYySElLWkJuZ05VbE9hekJ2NWlTWVRWN3VBeXBkdEhWRFlQSF95VExYTXhqb1dSMmxRcWM5MUlxWmhqSEtvTFl6U1hTV3NXRkJIWlVTeDhvTmpqaUVDbGpJbWhTclZET0tr?oc=5","date":"2025-04-11","type":"deal","source":"Business Wire","summary":"Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value - Business Wire","headline":"Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOSVJVZktSRGVFeGdqc3RlNTRoc0FFR0ZteU5wNXBianRQZUNMdnNsYktxTjVLVFdVeko3bDVTTTZFbzRnVC04VjQwMkF0MEpUYkFMNERIUjVfWmN2c3E0TWdIeE15MmlETVkzbmdNMU9CNXJtc2tDbFRibkFPeUVtZ09lTkFSaDQ5V1NhWWVNdEtMeFZlblQ2MnViai1qNERvZXc?oc=5","date":"2025-03-26","type":"regulatory","source":"Contract Pharma","summary":"Theratechnologies Receives FDA Approval for EGRIFTA WR - Contract Pharma","headline":"Theratechnologies Receives FDA Approval for EGRIFTA WR","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPM3NIUVpTU0x2OXF0V0RYeWtKMlc1ZFVNQmJtandvZ0tMeDFWYXVsSWw1VTZGQzcxRWxDSElYTE5xb1VJdG9Xa2VKMXlFRDZ6RmdWcE11X0E3bXFMVTB3UFQtd1E0VFBuVVZaYlJuQkU5QmN6Z19OY3oxQXNMREdDQ0VzblNjTEpJa1k4bEtTbXRVVU16elFZenRadXJJY1BnU0xqdS01VEY?oc=5","date":"2025-03-26","type":"regulatory","source":"The Pharma Letter","summary":"New Egrifta formulation picks up US FDA nod - The Pharma Letter","headline":"New Egrifta formulation picks up US FDA nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNOVpfMWJBbFR3WThfbkFjX3FUYkpjcFA4Vm1Hb1ZxdG9WYllTMjlycWtseXMwNWhvS3lRTnNET3ZpY3BLcTdiVFJoVHQ4bkVCb3c5R0k5bEs0bjJnZzhJWWJLeElPS1RxY1liTXE1NHdJNW5CYWpNSzZDcU85azZkeGlyTEdnYTlQQXo2Z19RVlpicXdwU3BKeTdDaFlhN2lPX2hxU2kyS05UeXY2T3ZwZ21PUHFTMl9iWUpuUjJfVzZZMXM1UG1GZV9jSVBMZjI0Q3k5dEltMzE0SGp0SEZBSmRoTVNRelJXelhFUHNpZkNRcmlGTUNhUTJJY2Z5RllXQjhhYzJ4SHVLQWpKZ0lqM2w4M1ZVdDE4am9iWlEyaw?oc=5","date":"2024-12-04","type":"pipeline","source":"GlobeNewswire","summary":"Theratechnologies Announces Exclusive Licensing Agreement - GlobeNewswire","headline":"Theratechnologies Announces Exclusive Licensing Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOZjYyY2tlLXhzbGY5cWFGaGdwMVBRWHpUWkhFbGJCZEdidi1XQjZhLUEwV29KaG12SW9Tay1fWWZSRFZmdTVSbHJHek9MdkZnTWtkSndtTDkydFVSV0xhdGwtQkhRZ21oOXBqOVRtTGhIX0lmRV9kbkJXUmpjZEItSk84SVh3TFN5TjI4ejA3MG9IcERiTnJaSXNsVEtPdVRUbTB0SExYYWtzeUJuV29zUnNNZEpGMjQyVTJpY19UX19xMzVMRlMyS3NiVUpmcWpqNWhmQi1EVDBzcVItbGV6RmdNTDFuUFFOekgzOG81VQ?oc=5","date":"2023-02-23","type":"trial","source":"BioPharma APAC","summary":"Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV - BioPharma APAC","headline":"Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV","sentiment":"positive"}],"patents":[{"drugName":"Tesamorelin","drugSlug":"tesamorelin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":2,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Merck & Co.","ViiV Healthcare"],"therapeuticFocus":["HIV","Oncology"],"financials":{"source":"sec_edgar","revenue":320635000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":320635000,"period":"2025-12-31"},{"value":386272000,"period":"2024-12-31"},{"value":563608000,"period":"2023-12-31"},{"value":501985000,"period":"2022-12-31"},{"value":291337000,"period":"2021-12-31"},{"value":225148000,"period":"2020-12-31"}],"grossProfit":42659000,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-37121000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":8348000,"cashHistory":[],"totalAssets":530205000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.82,"previousClose":13.73,"fiftyTwoWeekHigh":14.21,"fiftyTwoWeekLow":5.97,"fiftyTwoWeekRange":"5.97 - 14.21","fiftyDayAverage":8.26,"twoHundredDayAverage":7.97,"beta":1.12,"enterpriseValue":1375154432,"forwardPE":44.6,"priceToBook":3.54,"priceToSales":4.32,"enterpriseToRevenue":4.29,"enterpriseToEbitda":32.31,"pegRatio":0,"ebitda":42565000,"ebitdaMargin":13.3,"freeCashflow":17257124,"operatingCashflow":74092000,"totalDebt":10696000,"debtToEquity":2.7,"currentRatio":0.87,"returnOnAssets":-3.1,"returnOnEquity":-9.2,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":13.67,"targetHighPrice":15,"targetLowPrice":11,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.2,"institutionHeldPercent":97.9,"sharesOutstanding":100153204,"floatShares":32364508,"sharesShort":2644780,"shortRatio":5.35,"shortPercentOfFloat":2.6,"epsTrailing":-0.37,"epsForward":0.31,"revenuePerShare":3.22,"bookValue":3.9,"officers":[{"age":54,"name":"Mr. James Bradley Archer","title":"CEO, President & Non-Independent Director"},{"age":46,"name":"Mr. Jason Paul Vlacich","title":"Chief Financial Officer"},{"age":50,"name":"Mr. Troy C. Schrenk","title":"Executive VP of Operations & Chief Commercial Officer"},{"age":52,"name":"Ms. Heidi Diane Lewis J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":36,"name":"Mr. Brendan  Dowhaniuk","title":"Executive Vice President of Strategy & Corporate Development"},{"age":null,"name":"Mr. Cyril J. Hahamski","title":"Chief Accounting Officer"},{"age":null,"name":"Mr. Mark  Schuck CPA","title":"Senior Vice President of Investor Relations & Financial Planning"},{"age":null,"name":"Mr. Scott  John","title":"Senior Vice President of Marketing & CX"}],"industry":"Specialty Business Services","irWebsite":"","website":"https://www.targethospitality.com","phone":"800 832 4242"}}